Site Occupation

Background

Site Occupation

Glycosylation is one of the most common protein post-translational modifications. At least 50% of human proteins are glycosylated. N-, O-linked glycans are required to maintain the biological functions of proteins. Insufficient glycosylation can lead to animal and plant diseases. Therefore, characterizing the degree of glycosylation on proteins is an important step in understanding the diagnosis and treatment of diseases. N-, O-glycosylation is also closely related to various biological events, including cancer metastasis, virus infection and antibody-antigen interactions, so the accurate determination of site occupancy is essential to fully understand the impact of protein glycosylation on human health. Unlike N-glycosylation, it is more difficult to analyze O-linked glycans due to the lack of universal enzymes for releasing O-glycans from proteins and the high degree of heterogeneity in their occupation.

Glycoprotein analysis requires the determination of glycosylation sites and the glycan structure associated with each site. In recent years, a wide range of analysis methods based on mass spectrometry have been developed. These methods require high resolution and sensitivity so that glycosylation sites and micro-heterogeneity information can be obtained.

Our Services

Advantages of Us

  • High sensitivity and high throughput
  • Multiple technology platforms
  • Strict quality control management
  • Professional scientific research team and sophisticated equipment
  • One-stop services

CD BioGlyco is an experienced company in the analysis of glycosylation site occupation. Our multi-functional analysis platform and powerful database can provide customers with a diverse portfolio of glycosylation analysis services, and our excellent services have helped us gain a good reputation worldwide. We hope to start the exploration of glycobiology with you.

Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.

Reference:

  1. Stavenhagen, K.; et al. Site-specific N- and O-glycosylation analysis of atacicept. MABS. 2019: 1-11.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.